Elezanumab

立即咨询

Elezanumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1791416-49-3

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

依来努单抗
ABT-555
AE12-1Y-QL
Anti-RGMA Reference Antibody (elezanumab)

产品介绍

Elezanumab (ABT-555; AE12-1Y-QL) 是一种人单克隆抗体，可选择性靶向排斥性引导分子 A (RGMa)。Elezanumab 通过 SMAD1/5/8 通路有效抑制 RGMa 介导的 BMP 信号传导，IC₅₀约为 97 pM。Elezanumab 促进神经元损伤和脱髓鞘模型中的神经再生和神经保护作用，可结合 N 末端 RGMa、阻断 BMP 信号传导并缺乏 RGMc 交叉反应性。Elezanumab 具有神经再生和神经保护活性，对铁代谢没有影响。

生物活性

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targetsrepulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism^[1]^[2].

体内研究
(In Vivo)

Elezanumab (ABT-555; AE12-1Y-QL; 1-10 mg/kg; 静脉给药; 每周一次; 共 5 剂) 在视神经挤压和视神经炎雌性 Lewis 大鼠模型中促进轴突再生并防止视网膜神经纤维层退化^[1]。
Elezanumab (0.01, 0.1, 1, 10 mg/kg; 静脉给药; 每周一次; 共 3 剂) 在脊柱靶向实验性自身免疫性脑脊髓炎 (EAE) 雌性 Lewis 大鼠模型中促进轴突再生和髓鞘再生，减少炎症病变面积并改善功能恢复^[1]。

Animal Model:	Female Lewis rat optic neuritis models^[1]
Dosage:	1, 3, or 10 mg/kg
Administration:	IV; once a week for 5 doses
Result:	Protected against the optic nerve inflammationinduced RNFL degeneration. Showed significant protection of the RNFL, as demonstrated by decreased reduction in RNFL thickness measured by optical coherence tomography (OCT) with 10 mg/kg

CAS 号

1791416-49-3

中文名称

依来努单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.